TPP1 and glycogen storage disease VI: A phase 1/2 open‐label dose‐escalation study to evaluate safety, tolerability, pharmacokinetics, and efficacy of intracerebroventricular BMN 190 in patients with late‐infantile neuronal CLN2 disease